Actual Medicinal Product (AMP) Adizem-XL 180mg capsules (Napp Pharmaceuticals Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label. Mitigation measures may need to be considered. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
- Notes
-
Should be stored in airtight, light-resistant containers. Excessive humidity should be avoided.
- Provenance
-
This compatibility recommendation is derived from Adizem-SR and XL 180mg capsules (Napp Pharmaceuticals Ltd), Angitil SR 180 capsules (Ethypharm UK Ltd), Viazem XL 180mg capsules (Thornton & Ross Ltd) and Zemtard 180 XL capsules (Galen Ltd).
- Generic
- Diltiazem
- Formulation
- Diltiazem 180mg modified-release capsules
-
Diltiazem
-
Diltiazem 180mg modified-release capsules
-
Adizem-XL 180mg capsules (Napp Pharmaceuticals Ltd)
-
-
Diltiazem 60mg modified-release capsules